Hydroxyurea interaction with &#945;7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19.

Lykhmus, Olena; Kalashnyk, Olena; Sullivan, Raymond; Skok, Maryna

Hydroxyurea interaction with α7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19.

Lykhmus, Olena; Kalashnyk, Olena; Sullivan, Raymond; Skok, Maryna.

Afiliação

Lykhmus O; Palladin Institute of Biochemistry, Kyiv, Ukraine.
Kalashnyk O; Palladin Institute of Biochemistry, Kyiv, Ukraine.
Sullivan R; Greensboro, NC 27455, USA.
Skok M; Palladin Institute of Biochemistry, Kyiv, Ukraine. Electronic address: skok@biochem.kiev.ua.

J Neuroimmunol ; 385: 578244, 2023 12 15.

Article em En | MEDLINE | ID: mdl-38016403

Assuntos

COVID-19; Receptores Nicotínicos; Humanos; Receptor Nicotínico de Acetilcolina alfa7/genética; Hidroxiureia/farmacologia; Hidroxiureia/uso terapêutico; SARS-CoV-2/metabolismo; Anti-Inflamatórios/uso terapêutico

Palavras-chave

Angiotensin-converting enzyme-2; Hydroxyurea; Immunoglobulin glycosylation; Inflammation; SARS-Cov-2; α7 nicotinic acetylcholine receptor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores Nicotínicos / COVID-19 Limite: Humans Idioma: En Revista: J Neuroimmunol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google